Sonali Narain
YOU?
Author Swipe
View article: A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus
A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus Open
Objective Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progressio…
View article: Implementation outcomes of a patient decision-aid in a diverse population with systemic lupus erythematosus in 15 US rheumatology clinics
Implementation outcomes of a patient decision-aid in a diverse population with systemic lupus erythematosus in 15 US rheumatology clinics Open
Objective The objective of this study was to examine the clinical outcomes during the implementation of a self-administered patient decision-aid (PtDA) for lupus. Methods We provided an effective computerized lupus PtDA in 15 rheumatology …
View article: Factors associated with immune responses to SARS-CoV-2 vaccination in individuals with autoimmune diseases
Factors associated with immune responses to SARS-CoV-2 vaccination in individuals with autoimmune diseases Open
To study responses to COVID-19 vaccine in autoimmune patients
View article: Belimumab treatment of adult idiopathic inflammatory myopathy
Belimumab treatment of adult idiopathic inflammatory myopathy Open
Objective To evaluate belimumab addition to the standard of care in patents with refractory idiopathic inflammatory myopathy (IIM). Methods We conducted a 40-week multicentre, randomized, double-blind, placebo-controlled trial with 1:1 IV …
View article: A Multianalyte Assay Panel With Cell‐Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology–Classified Lupus
A Multianalyte Assay Panel With Cell‐Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology–Classified Lupus Open
Objective To evaluate the usefulness of biomarkers to predict the evolution of patients suspected of systemic lupus erythematosus (SLE), designated as probable SLE (pSLE), into classifiable SLE according to the American College of Rheumato…
View article: Comparative Survival Analysis of Immunomodulatory Therapy for COVID-19 ‘Cytokine Storm’: A Retrospective Observational Cohort Study
Comparative Survival Analysis of Immunomodulatory Therapy for COVID-19 ‘Cytokine Storm’: A Retrospective Observational Cohort Study Open
Background Cytokine storm is a marker of COVID-19 illness severity and increased mortality. Immunomodulatory treatments have been repurposed to improve mortality outcomes. Methods We conducted a retrospective analysis of electronic health …
View article: Cell-bound complement activation products associate with lupus severity in SLE
Cell-bound complement activation products associate with lupus severity in SLE Open
Objectives To evaluate the association between lupus severity and cell-bound complement activation products (CB-CAPs) or low complement proteins C3 and C4. Methods All subjects (n=495) fulfilled the American College of Rheumatology (ACR) c…
View article: Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE
Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE Open
Objective We compared the physician-assessed diagnostic likelihood of SLE resulting from standard diagnosis laboratory testing (SDLT) to that resulting from multianalyte assay panel (MAP) with cell-bound complement activation products (MAP…
View article: Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus
Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus Open
Objective To evaluate the frequency of cell‐bound complement activation products ( CB ‐ CAP s) as a marker of complement activation in patients with suspected systemic lupus erythematosus ( SLE ) and the usefulness of this biomarker as a p…
View article: 237 Cell bound complement activation products in combination with low complement C3 or C4 have high diagnostic yield in systemic lupus erythematosus
237 Cell bound complement activation products in combination with low complement C3 or C4 have high diagnostic yield in systemic lupus erythematosus Open
Background Cell Bound Complement Activation Products (CB-CAPs), are stable form of classical complement activation, ex-vivo, and sensitive and specific marker of SLE. In the present study, we sought to compare the performances of CB-CAPs t…
View article: An interim report of the Scleroderma Clinical Trials Consortium working groups
An interim report of the Scleroderma Clinical Trials Consortium working groups Open
The Scleroderma Clinical Trials Consortium represents many of the clinical researchers in the world who are interested in improving the efficiency of clinical trials in systemic sclerosis. The Scleroderma Clinical Trials Consortium has est…